Suicide is a leading cause of deathamong young people ages 20 to 24 in the United States, and the risk is even higher in individuals with type 1 diabetes. In fact, up to 7% of deaths in individuals with type 1 diabetes are a result of suicide. However, current screening tools for depression and suicide often miss individuals at risk of suicide and the risk among the type 1 diabetes patient population is greatly underestimated.

The symposium will highlight the work of RESCUE and address solutions for two distinct uncertainties faced by health care providers in the management of people with type 1 diabetes at risk of suicide: how to identify those at risk and the best way to prevent and reduce that risk.

Discussion topics will include:

"Suicide and self-harm are an all-too-common reality for young adults with type 1 diabetes, but it doesn't have to be. With a multi-pronged approach to awareness, education, and identification, we have the opportunity to intervene on the link between suicide and diabetes," said Professor Katharine Barnard-Kelly, PhD., RESCUE Collaborative Community. "With this symposium, it is our hope that we can reach stakeholders with awareness and arm them with messages that can ultimately save a young person's life if adopted in clinical practice and through mental health screenings."

Professor Katharine Barnard-Kelly, PhD and the RESCUE team will present during the symposium, Suicide and Self-InjuryUnveiling and Addressing the Hidden Nightmare in Diabeteson Friday, June 3 from 4:156:15 p.m. CT.

For more information, please contact the ADA Scientific Sessions media team onsite at the Ernest N. Morial Convention Center from June 37 by phone at 504-670-4902, or by email at [emailprotected].

About the ADA's Scientific SessionsThe ADA's 82nd Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be a hybrid event held June 37, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA. Leading physicians, scientists, and health care professionals from around the world will unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. We are eager to get back to safely participating in person and networking with colleagues while hearing the latest scientific advances and groundbreaking research presentations. Learn more and register atscientificsessions.diabetes.organd join the Scientific Sessions conversation on social media using #ADA2022.

About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 81 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 133 million Americans living with diabetes or prediabetes. Diabetes has brought us together, what we do next will make us Connected for Life. To learn more or to get involved, visit us atdiabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociacin Americana de la Diabetes),LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), andInstagram (@AmDiabetesAssn).

SOURCE American Diabetes Association

Read more here:
American Diabetes Association Symposium to Bring to Light the Impact of Suicide and Depression on Adolescents with Type 1 Diabetes - PR Newswire

A commercial drivers license (CDL) is a drivers license necessary to operate trucks and drive interstate. Previously, people with diabetes may not have met the criteria to get a CDL. However, while a person needs to meet numerous health requirements, it is possible for those living with diabetes to become truck and bus drivers.

Prior to 2003, there was a ban on trucking for individuals with insulin-treated diabetes, both type 1 and type 2.

In 2003, the Federal Motor Carrier Safety Administration (FMCSA), the agency regulating the trucking industry in the United States, began a system known as the Diabetes Exemption Program. Through this lengthy process, a person with insulin-treated diabetes could obtain an exemption to operate large trucks.

However, in 2018, the FMCSA ended the program. Instead, a person living with diabetes can obtain a Medical Examiners Certificate (MEC), a standard certification other drivers need to provide to confirm they are physically able to operate a commercial vehicle.

An individuals treating clinician completes the assessment form attesting that they have a stable insulin regimen and properly controlled diabetes.

In this article, we discuss how a person with type 2 diabetes can pass their CDL, what it involves, and how long it is valid. We also suggest tips for driving with diabetes.

Following the new ruling by the FMCSA for people living with diabetes in 2018, a person with type 2 diabetes can obtain their CDL.

The new rule reflects modern diabetes management and means there is no longer a blanket exclusion against insulin use.

Previously, it was more difficult for people with insulin-treated diabetes to obtain their CDL. However, the new ruling supports that people with diabetes can safely operate commercial motor vehicles.

According to the new regulations, individuals with type 2 diabetes who do not require insulin only need to follow their state guidelines to obtain and keep a CDL.

If a person with type 2 diabetes requires insulin, they will now only need to obtain a MEC to confirm they have a stable insulin regimen and are able to manage their condition.

Under the new ruling, a listed certified medical examiner (CME) can grant a person with insulin-treated diabetes a MEC for up to 12 months.

To do so, the healthcare professional who manages and prescribes insulin for the person provides the assessment form to the CME. The CME will then determine if the person meets the FMCSAs qualification standards.

These standards include:

The assessment will also detail whether the person has recently experienced a severe hypoglycemic episode or any potential complications due to type 2 diabetes.

The FMCSA estimates that the annual cost to comply with this ruling is $332, which is significantly lower than the cost prior to the 2018 rule change.

The maximum period of medical certification under the new rule is 12 months. This new ruling is applicable in every state and U.S. territory.

To be eligible for the maximum 12 months, an individual needs to be able to provide sufficient evidence that they are able to manage their condition.

This includes being able to provide at least the preceding 3 months of blood glucose self-monitoring records. Without this, a CME may only be able to provide them a 3-month certificate to allow them to collect the necessary records.

Living with diabetes can affect a persons ability to drive, as they need to ensure their blood sugars are at suitable levels and may develop complications that may make it more difficult to drive.

Some tips for driving may include:

For individuals living with type 2 diabetes, it may be advisable to try the following:

Following the new ruling the FMCSA introduced in 2018, it is easier for people with type 2 diabetes to obtain a CDL. Individuals with insulin-treated diabetes need to obtain a MEC to operate commercial motor vehicles.

The FMCSA keeps a registry of CMEs. These healthcare professionals determine whether a driver meets the FMCSAs physical qualification standards to hold a CDL. This certification is valid for 12 months and enables a person to obtain a CDL.

Read the original here:
Can a person pass their CDL if they have type 2 diabetes? - Medical News Today

DALLAS May 31, 2022 The rapid adoption of telemedicine and increased use of continuous glucose monitoring helped to attenuate the impacts of the COVID-19 pandemic on children with Type 1 diabetes, according to a new study from UTSouthwestern researchers.

Abha Choudhary, M.D.

The pandemic had profound effects on disease management when shutdowns occurred in 2020, creating barriers for those who lost jobs and insurance and aggravating existing health disparities. Several studies have shown that the pandemic worsened glucose control in patients with diabetes and made it more difficult to access care.

Our diabetes team implemented telemedicine visits within weeks of the shutdown, allowing us to provide care to our patients in an efficient and timely manner, said Abha Choudhary, M.D., Assistant Professor of Pediatrics at UTSouthwestern and a pediatric endocrinologist at Childrens Health. Our team was also able to utilize continuous glucose monitoring for a growing number of patients which may have helped to mitigate some of the challenges brought on by the pandemic.

For the study published in BMC Pediatrics, Dr. Choudhary and colleagues used data from Childrens Medical Center Dallas to determine how the management of patients with Type 1 diabetes was affected by the pandemic in a large urban setting. They analyzed patient characteristics including insurance status, race, ethnicity, gender, glucose control, office visits, and hospitalizations, and compared the use of continuous glucose monitoring in the year prior to the start of the pandemic to the first year of the pandemic.

The study found that while the number of office visits among patients decreased during the pandemic, there was no effect on disease management in this group both glucose control and hospitalization rates were unchanged.

However, the results highlighted existing disparities among patients in minority and low-income demographics. Both before and during the pandemic, Black and Hispanic patients and those without commercial insurance had worse glucose control and higher hospitalization rates than their white, non-Hispanic, insured counterparts.

While the use of continuous glucose monitoring was higher among insured patients overall, there was a dramatic increase in use by patients without commercial insurance during the pandemic. This is likely due to the increased availability of glucose monitoring systems offered to Medicaid recipients in Texas that took effect during the pandemic, Dr. Choudhary explained.

The researchers believe the increased use of continuous glucose monitoring along with the successful implementation of telemedicine greatly contributed to preventing worse outcomes in this patient population.

For all the progress we have made, significant disparities remain with regard to access to some of the tools we think made the biggest differences during the early months of the pandemic, said Dr. Choudhary. From broadband access to the hardware and software thats so central to diabetes care these days, weve only begun to scratch the surface when it comes to addressing disparities in technology and remote-patient monitoring.

UTSouthwestern is ranked among the top 25 hospitals in the nation for diabetes and endocrinology by U.S. News & World Report.

About UTSouthwestern Medical Center

UTSouthwestern, one of the nations premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 26 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,900 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in more than 80 specialtiesto more than 100,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 4 million outpatient visits a year.

Read more:
Telemedicine, continuous glucose monitoring mitigated effects of pandemic on children with diabetes - UT Southwestern

Users of insulin pumps may be used to a certain regimen associated with managing their diabetes. That can include carbohydrate counting, setting basal rates and more.

Beta Bionicshas set out to change that. With the Concord, Massachusetts-based companys iLet bionic pancreas, the user inputs just one number: their body weight.

The company designed the pocket-sized, wearable, investigational iLet device to autonomously dose insulin. Worn like an insulin pump, iLet users only enter body weight to initialize therapy without the need for insulin regimen parameters. The company designed the device to then automatically titrate and infuse insulin without requiring the counting of carbs, the settings of certain rates and factors and more.

Its very qualitative, not quantitative, Beta Bionics interim CEO and board member Martha Aronson toldDrug Delivery BusinessNews. This cognitive burden the amount of math you have to do every day if youre a person with type one diabetes is extraordinary. Our goal is to take away that cognitive burden for people who live with type one diabetes.

Get the full story at our sister site, Drug Delivery Business News.

Read more from the original source:
Beta Bionics looks to reduce 'cognitive burden' for those with diabetes with bionic pancreas - Mass Device

For the first time ever, WHO Member States have supported the creation of global targets for diabetes, as part of recommendations to strengthen and monitor diabetes responses within national noncommunicable disease (NCD) programmes.

The five new targets set the standard that, by 2030:

The aim is to reduce the risk of diabetes, and move towards a world where all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable and quality treatment and care.

The recommendations and targets are a core part of work requested by Member States in a resolution at last years World Health Assembly (A74/A/CONF./5). This resolution also requested the WHO Secretariat to:

Far too many people with diabetes have either never been diagnosed or are not able to access the medicines and technologies that could improve their condition. said Dr Bente Mikkelsen, Director for Noncommunicable Diseases, WorldHealth Organization.

As one example, it is unacceptable that a century since the discovery of insulin, many people still cannot access this essential and life-saving medicine. The decision taken today, including the establishment of global coverage targets for diabetes, will empower Member States to accelerate action on diabetes, and support people living with diabetes, around the world.

A year of the Global Diabetes Compact

Much has happened since the launch of the Global Diabetes Compact at the 2021 Global Diabetes Summit, co-hosted by WHO and the Government of Canada to commemorate the 100th anniversary of the discovery of insulin. Six workstreams have beenestablished, covering vital areas such as access to essential medicines and health technologies, health promotion, and country work. Work has also been taken to implement the Global Diabetes Compact at Regional Office level.

WHO has secured the assistance of leading experts to advise on diabetes technical matters, through the establishment of a Technical Advisory Group on Diabetes (TAG-D). We are also learning from people with lived experience of diabetes, acknowledging thatthis principle will help ensure the Global Diabetes Compact focuses on areas where action is most needed.A global informal consultation and focus groups have been conducted with people with lived experiences of diabetes, yielding vital insightson several topics including diabetes care, education, mental health and stigma associated with diabetes.

In addition, two meetings of the recently formed Global Diabetes Compact Forum have been held, with more than 70 participating organizations from civil society, academic institutions, philanthropic foundations, and business associations. The Forum providesan opportunity for the exchange of information and ideas that could be organized collectively for greater impact.

Scaling up our impact in countries around the world

The establishment of the Global Diabetes Compact and its associated coordination activities have brought added impetus to diabetes efforts within ministries of health around the world. Across the three levels of WHO, teams have used the opportunity tosupport countries in their efforts, providing technical guidance and support advocacy.

Over the past few months, WHO has secured funding for a 3-year project on the prevention and control of NCDs in primary care by prioritizing people living with diabetes in Kyrgyzstan and Uzbekistan.

WHO has been working hard to integrate diabetes into primary care, using the WHO Package of Essential Noncommunicable disease interventions (PEN) toolkit and HEARTS technical package. Mali is one of seven countries in the African Region currently implementingWHO HEARTS, including training health-care workers on managing diabetes. In South-East Asia, WHOs technical guidance on diagnosis and management of type 2 diabetes (HEARTS-D), has been adapted into an online training module for stakeholdersresponsible for planning diabetes services.

Every year until 2031, the WHO Secretariat will also submit a report on the implementation of the recommendations to the Health Assembly through the Executive Board, on an annual basis and as a component on the report on NCDs.

Link:
First-ever global coverage targets for diabetes adopted at the 75th World Health Assembly - World Health Organization

According to theCDC1, in the last 20 years, the number of adults diagnosed with diabetes has more than doubled as the American population has aged and become more overweight or obese. In addition, one study2 concluded that 3 out of 10 adults, or about 8 million people, have diabetes but aren't aware of it.

RBGM is an easy way for physicians to monitor patients that may be at risk for diabetes or patients with diabetes by simply providing a device they can take home. The iGlucose from Smart Meter utilizes the 4/5G AT&T IoT fast and secure network so patients and providers can track blood glucose levels in real time. This allows the provider to make an immediate diagnosis and implement a care program to improve outcomes.

A great example of the impact a remote blood glucose monitoring program can have on outcomes was seen at the Leon Medical Centers in South Florida. In 2021, Working with the Rimidi RPM platform, Leon patients who were considered high-risk with A1c levels above 9% were given an iGlucose and instructed by their doctor how often to take their blood-glucose reading. Of the approximately 225 high-risk patients who were enrolled in the program, 84% of those patients saw a reduction in their A1Cs below 9%, a key indicator of better diabetes control.

"In recent years, it's been proven that digitally connecting patients to their doctors between visits improves care and outcomes," said Casey Pittock, CEO, Smart Meter. "The conclusions of the program for Leon Medical Centers' patients are another example of how powerful RBGM can be. By providing these patients with a cellular-enabled iGlucose that transmits results immediately, it eliminated many barriers to reliable data that are seen with Bluetooth devices."

While remote patient monitoring has become more popular in recent years, education about its benefits is still needed. In fact, 45% of respondents in a Smart Meter study3 have never heard of RPM. Those who have heard of RPM programs overall feel it would help them increase their testing frequency.

About Smart Meter, LLC

Now working with more than 300 RPM distribution partners, who serve more than 120,000 patients, Smart Meter is the leading supplier of cellular-enabled virtual care technologies that include the iGlucose, iBloodPressure, iPulseOx, iScale, and SmartRPMcloud platform, as well as data, and services. Smart Meter's remote patient monitoring solutions are recognized as the standard for the RPM industry and are regarded for their high patient retention and satisfaction. The unique combination of reliable health data, patient-friendly devices, and platform integrations enable and enhance RPM, CCM, Employee Wellness, Population Health, and Telehealth programs for. For more information, visitSmartMeterRPM.com

1 Diabetes Quick Facts | Basics | Diabetes | CDC

2Nearly 3 in 10 Americans With Diabetes Don't Know It: Study - Consumer Health News | HealthDay

3Smart-Meter-National-Diabetes-Month-Survey.pdf (smartmeterrpm.com)

Smart Meter, LLC Media Contact5501 W. Waters Ave., Suite 401 Keith TolbertTampa, FL 33602 [emailprotected]813-773-4080 336-509-8024

SOURCE Smart Meter, LLC

Link:
RPM Software Provider Helps a Clinic Reduce A1c Levels for 84% of Patients Enrolled in a Program that Used the Cellular-Enabled iGlucose for Remote...